Symposium

ShareInvestor celebrates 25th anniversary; Holding company rebrands as AlphaInvest

Retrieved on: 
星期四, 四月 11, 2024
ACRA, Senior management, Social media, Accounting, Symposium, Non-fungible token, Generation Z, SPH, PTSI, Face, Consultant, Singapore Press Holdings, Calendar, Security (finance)

Ltd., the holding company of Singapore's largest independent platform for retail investors, today announced a name change and a new logo to mark its 25th anniversary.

Key Points: 
  • Ltd., the holding company of Singapore's largest independent platform for retail investors, today announced a name change and a new logo to mark its 25th anniversary.
  • The new holding company identity coincides with the Group's 25th anniversary of its founding in 1999.
  • The Group's holding company has been registered with the Accounting and Corporate Regularity Authority (ACRA) as "AlphaInvest Holdings Pte.
  • AlphaInvest is currently the organiser of several prominent events on the annual investing calendar such as InvestFair and the REITs Symposium.

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

Retrieved on: 
星期一, 五月 6, 2024
Chin Na, OTCQB, Food, Symposium, AC5, Patient, SAWC, Human, Wound healing, Therapy, Orlando World Center Marriott, User experience, Nursing

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Key Points: 
  • FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
  • Arch’s team will be available for discussions with clinicians throughout the Symposium and at Arch’s booth (#535) in the exhibit hall.
  • Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted that AC5 Advanced Wound System will be presented again at this important Symposium.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Brain, Ecosystem, LEAP, Dyno, Symposium, Cell, AAV, Intelligence, Engineering, Human, DNA, Patient, Wrist, Gene, Eye, Society, NVIDIA, Annual general meeting, Therapy, Vaccine

The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery.

Key Points: 
  • The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery.
  • These results demonstrate the potential of these AI methods to broaden the number of patients who can benefit from gene therapy using synthetic capsids for gene delivery.
  • The work will help advance design capabilities for gene therapies and other sequence-based medicines with potential for transformative patient impact.
  • The collaboration will focus on scaling Dyno’s pioneering “lab-in-the-loop” sequence design approach using NVIDIA’s optimized cloud and BioNeMo platforms.

The Modern Data Company Chosen as Finalist for the 2024 MIT Sloan CIO Symposium’s Innovation Showcase

Retrieved on: 
星期二, 五月 7, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, Organizational founder, Multimedia, Enterprise, Symposium

The Modern Data Company, a leader in data product lifecycle management and the inventor of the world’s first data operating system, DataOS®, today announced its selection as a finalist in the 2024 Innovation Showcase at the 21st annual MIT Sloan CIO Symposium.

Key Points: 
  • The Modern Data Company, a leader in data product lifecycle management and the inventor of the world’s first data operating system, DataOS®, today announced its selection as a finalist in the 2024 Innovation Showcase at the 21st annual MIT Sloan CIO Symposium.
  • View the full release here: https://www.businesswire.com/news/home/20240507194077/en/
    This prestigious selection recognizes The Modern Data Company as a leading innovator in the Enterprise IT sector.
  • Among ten early-stage companies chosen, The Modern Data Company stands out for its groundbreaking data management solutions that deliver tangible value to businesses.
  • “We are thrilled to be selected as a finalist for the MIT Sloan CIO Symposium’s Innovation Showcase,” said Srujan Akula, CEO and Cofounder of The Modern Data Company.

RE/MAX Elevates Commercial Business with 12th Annual Global Commercial Symposium

Retrieved on: 
星期三, 五月 8, 2024
Real estate, Learning, Consumer, Commercial, RE/MAX, Symposium, Senior, The Land Institute, Broker, Property management

DENVER, May 8, 2024 /PRNewswire/ -- RE/MAX, LLC, the #1 name in real estate1, announces the highly anticipated 2024 RE/MAX® Global Commercial Symposium, slated from June 10-12 at the Tampa Bay Marriott Water Street in Florida. With a lineup of dynamic speakers, the event offers a unique opportunity for RE/MAX Commercial Brokers to strengthen their skills and for all affiliates to explore the realm of commercial real estate.

Key Points: 
  • The annual RE/MAX Commercial event zeroes in on helping build Commercial Brokers' business, June 10-12 in Tampa
    DENVER, May 8, 2024 /PRNewswire/ -- RE/MAX, LLC, the #1 name in real estate1, announces the highly anticipated 2024 RE/MAX® Global Commercial Symposium, slated from June 10-12 at the Tampa Bay Marriott Water Street in Florida.
  • With a lineup of dynamic speakers, the event offers a unique opportunity for RE/MAX Commercial Brokers to strengthen their skills and for all affiliates to explore the realm of commercial real estate.
  • It comprises more than 11,000 commercial brokers in over 640 commercial offices and divisions.
  • Also new this year, RE/MAX Commercial is announcing a new tech platform with RealNex, a leading commercial real estate technology company.

Leading Experts Examine Patient-Centered Health Care Across the Lifespan at National Health Council Science of Patient Engagement Symposium

Retrieved on: 
星期三, 五月 8, 2024
Science, FDA, Ageism, Patient, Woman, Pediatrics, NHC, Symposium, Doctor of Philosophy, Research, Artificial intelligence, Adolescence, Survivor, FAAFP, Principal, MPH, Press club, Caregiver, Diagnosis, Visual impairment, Food and Drug Administration, National Health Council, Nursing

WASHINGTON, May 8, 2024 /PRNewswire/ -- Leading health care experts asked health care providers and policymakers to keep patients of all ages at the center of their decision-making process during the National Health Council (NHC) 2024 Science of Patient Engagement Symposium. The conference, entitled, Patient Experiences through their Lifespan, held May 8-9 at the National Press Club, brings together more than 180 policymakers, researchers, patients and patient advocates, and health care providers.

Key Points: 
  • The conference, entitled, Patient Experiences through their Lifespan , held May 8-9 at the National Press Club, brings together more than 180 policymakers, researchers, patients and patient advocates, and health care providers.
  • The Science of Patient Engagement Symposium explores standards and best practices that ensure every patient has legitimate input in their own medical care and that patient research results are applied equally to all individuals.
  • Today's Symposium also explores meaningful patient engagement, defined as patients who are recognized as equal partners and integrated in the development phases of science, research, and drug regulation.
  • The Science of Patient Engagement Symposium is an annual event where research leaders convene to share their experiences, accomplishments, best practices, and resulting translational impacts on the science of patient engagement.

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Retrieved on: 
星期四, 四月 25, 2024
Symposium, WHS, Patient, SAWC, Wound, European Wound Management Association, Wound healing, EWMA, Nursing

YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

Key Points: 
  • The oral presentations on EscharEx will include:
    Comparative data of EscharEx vs. SANTYL® that demonstrate EscharEx’s superiority over the current leading enzymatic debridement agent
    New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing
    These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care.
  • Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
  • "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL®, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound.
  • "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

Africa’s Tax Experts Unite in Nairobi for Landmark Symposium and Masterclass!

Retrieved on: 
星期二, 四月 23, 2024
Knowledge, Transfer, International taxation, Symposium, CSAT

It offers a unique opportunity for tax professionals to engage in critical discussions about the issues shaping the future of African tax landscapes.

Key Points: 
  • It offers a unique opportunity for tax professionals to engage in critical discussions about the issues shaping the future of African tax landscapes.
  • With a focus on practical challenges, participants will delve into navigating domestic regulations, tax treaties and the complexities of tax in trade and investment.
  • In addition to gaining valuable knowledge, attendees will have the opportunity to network with fellow tax professionals and exchange insights with leading experts.
  • Register today for the 9th Africa Tax Symposium and Masterclass, where knowledge, collaboration and innovation converge.

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

Retrieved on: 
星期四, 四月 11, 2024
Cloud, Society, Cancer, ICAD, Radiology, Health equity, Mammography, AI, Google Cloud, SBI, Partnership, Symposium, 3D, PACS, Patient, 2D, Breast cancer, Architecture, Medical imaging

In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.

Key Points: 
  • In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.
  • “We’re excited to highlight our recent notable advancements at the SBI annual symposium this year,” said Dana Brown, President and CEO of iCAD.
  • Visitors to the iCAD booth will also be able to witness the new advanced workstation features for ProFound Detection for both 2D and 3D mammography in its latest V3 Service Pack update.
  • Symposium attendees are invited to visit iCAD’s booth #512 or schedule a meeting at https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetin... to discuss iCAD’s newest partnerships and product demonstrations.

MIT Sloan CIO Symposium Selects Finalists for 2024 Innovation Showcase

Retrieved on: 
星期三, 四月 24, 2024
Intelligence, Hallucination, Risk management, Enterprise, Symposium

CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- The 21st annual MIT Sloan CIO Symposium, today announced the 10 finalists for its 2024 Innovation Showcase. The selected outstanding early-stage companies have developed cutting-edge solutions that combine both value and innovation to the Enterprise IT space. The finalists will receive key exposure to many of the world's most creative and influential IT executives at the in-person Symposium from May 13-14, 2024.

Key Points: 
  • Winners include early-stage companies in artificial intelligence, cybersecurity and data
    CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- The 21st annual MIT Sloan CIO Symposium , today announced the 10 finalists for its 2024 Innovation Showcase .
  • The finalists will receive key exposure to many of the world's most creative and influential IT executives at the in-person Symposium from May 13-14, 2024.
  • "We are thrilled to announce the finalists of the 2024 Innovation Showcase, which is held each year in conjunction with the MIT Sloan CIO Symposium," said Anton Teodorescu, Chair of the Innovation Showcase.
  • The 10 Innovation Showcase Finalists for 2024 are:
    We help IT Leaders make their old software new again through modernization, faster than anyone else in the industry.